Itb-med Llc

This study tested a new drug, TCD601, to see if it is safe and works as well as the standard drug (rATG) to prevent a patient's body from rejecting a new kidney after transplant. It involved 33 adults who received a kidney from a donor. The main goal was to check for side effects…

This study tested a new approach to help kidney transplant recipients safely stop taking lifelong anti-rejection medications. It combined a special drug (siplizumab) with an infusion of cells from the kidney donor and mild chemotherapy. The goal was to find the best treatment pla…